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ABSTRACT
Phyllanthus niruri is a plant with medicinal properties. It is often used to treat mild malaria and the elimination of renal stones. However, 
studies on its toxicity are scarce. The study was carried out to determine if the aqueous leaf extract of P. niruri administered to female 
Sprague-Dawley rats would illicit evidence of toxicity. Fifteen female rats weighing 150–200 g were divided into 3 groups. Rats in 
Group 1 were given a single low dose (LD) of 2 000 mg/kg b.w. of the extract by oral gavage within 24 hrs. Rats in Group 2 were 
given a single high dose (HD) of 5 000 mg/kg b.w. of the extract by oral gavage within 24 hrs. Rats in Group 3 were not given any 
extract but drinking water and served as the control group (C). All the rats were observed for signs of toxidromes for 14 days. On 
the 15th day, all the rats were sacrificed. Body organs were harvested for macroscopic examination. Urine and blood samples were 
drawn and analyzed. Hematological tests performed included full blood count and hemoglobin. Biochemical examinations included 
bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein, albumin, globulin, alkaline phosphatse (ALP), 
γ-glutamyltranspeptidase (GGT), urea, and creatinine. The results of the three groups were not significantly different. Examination of 
the various body organs did not show any abnormality. Thus no toxicity was observed at the levels administered. The LD50 of the 
aqueous extract is > 5 000 mg/kg. b.w.
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P. niruri have been attributed to geraniin (Srividya & 
Periwal, 1995), and confirmed by its cholesterol and tri-
glyceride lowering effects (Adeneye et al., 2006). Geraniin 
also possesses antiulcer properties and is believed to be 
seven times more potent than aspirin or acetaminophen 
(Miguel et al., 1996; Santos et al., 1994). The anti-malarial 
activity of P. niruri in 20 crude extracts from nine African 
medicinal plants used in Kinshasa, Congo, was confirmed 
(Tona et al., 1999; Cimanga et al., 2004; Mustofa et al., 
2007). P. niruri and amarus are said to offer protection 
against HBV (Mehrotra et al., 1990), chemical toxins (Lee 
et al., 2006; Chatterjee et al., 2006; Wang, 2000), liver can-
cer (Rajeshkumar and Kuttan, 2000) and tumorigenesis 
(Rajeshkumar et al., 2002; Sripanidkulchai et al., 2002), 
although the latter is still controversial (Milne et al., 1994; 
Doshi et al., 1994; Thamlikitkul et al., 1991). 
In this study, acute toxicity of P. niruri aqueous leaf 
extract was investigated because of limited information 
available on its toxicity, despite the widespread use of this 
medicinal plant.
Introduction
The Phyllanthus genus contains over 600 species dis-
tributed throughout the tropical and subtropical regions 
of the world. In the 1990s, a major reorganization of 
the Phyllanthus genus was conducted which classified 
P. amarus as a type of P. niruri (Taylor, 2003). P. niruri 
extract was demonstrated to block the formation of cal-
cium oxalate crystals (Campos and Schor, 1999; Freitas et 
al., 2002) and stone formation in urolithiasis (Barros et al., 
2003; Barros et al., 2006).
Recently, antispasmodic activity of P. niruri (Iizuka et 
al., 2006) and hypoglycemic effects were reported (Raphael 
et al., 2002; Ali et al., 2006). The hypotensive effects of 
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Methods
The protocol was reviewed and approved by the 
Institutional Animal Care and Use Committee of the 
Noguchi Memorial Institute for Medical Research 
(NMIMR) according to the Guidelines for Animal 
Experimentation. 
Plant material 
P. niruri leaves were collected from the Kpando area in 
the Volta region of Ghana in the month of September. 
The plant was identified in its vernacular names by the 
farmers and confirmed to be the same as those previ-
ously authenticated by the herbarium at the University of 
Ghana Botany Department. A specimen was lodged at the 
herbarium with voucher number GC1009.
Extract preparation
The leaves were air dried at room temperature to a con-
stant weight and ground to powder. The powder (1 800 g) 
was boiled in 3  000  ml of water for 15 minutes under 
atmospheric pressure and the solution was later filtered. 
The filtrate was lyophilized using a freeze-drying system, 
which yielded 33.27 g of freeze-dried material. The freeze-
dried sample was stored in a cool dry place until ready 
for use.
Animals and experimental design
Fifteen (15) female Sprague-Dawley (S-D) rats (weighing 
150–200 g) were obtained from the NMIMR. During the 
acclimatization period, clinical observations as well as 
body weight measurements of the animals were conducted 
and they were found healthy. The rats were assigned into 
groups including a control group by the stratified random 
method according to their body weight. S-D rats were fed 
standard chow diet (AIN-93G formulation, obtained from 
GAFCO – Ghana) ad libitum. 
Housing conditions
S-D rats were housed in metal cages with stainless steel 
tops in the animal care facility of NMIMR, where room 
temperature, humidity and ventilation were controlled 
according to international standards. The rats were main-
tained in a 12-h light-cycle and were studied for 14 days. 
Prior to sacrifice, they were anesthetized with diethyl 
ether and later euthanized. All visible organs and tissues 
were macroscopically examined and harvested. Blood 
collection was by cardiac puncture. 
Route of administration
The route of administration was by oral gavage in accor-
dance with the main route of intake of P. niruri decoction 
by humans for medicinal purposes. 
Acute toxicity test
Five S-D rats constituted a group. Thus three groups 
including the control group (C) were established. A 
single oral low dose (LD) of 2 000 mg/kg b.w. and a single 
oral high dose (HD) of 5  000 mg/kg b.w. P. niruri were 
reconstituted as aqueous homogenous suspensions. The 
administration volume was set at 900 μl / kg b.w. Group 1, 
the control group (C), fed normal chow diet, was gavaged 
162  μl drinking water (once). Group 2, low dose group 
(LD) and group 3, high dose group (HD) were gavaged 
with the extract at a single administration with the doses 
indicated previously. 
Clinical observations
The observation period was 14 days post administration. 
Clinical sings of toxidromes (rising fur, draping, tremors, 
excitability, miosis, mydriasis, twitching, salivation, mor-
bidity, etc.) and mortality were observed while dosing. 
Thereafter, daily observations were made until the 14th 
day. Body weights were measured before dosing on the day 
of administration and weekly thereafter.
Urinalysis
Urinalysis was performed on the 15th day. Urine was 
collected in the morning and examined for pH, protein, 
glucose, ketone bodies, bilirubin, occult blood and 
urobilinogen. 
Hematological indices
Hematological examinations were conducted on the 
15th day at necropsy. Blood samples were collected 
into EDTA-2K tubes for immediate analysis using 
the SYSMEX hematology autoanalyzer (Kobe, Japan). 
Reagents for the hematology autoanalyzer were obtained 
from STROMATOLYZER (WH, USA). Leukocyte count, 
erythrocyte count, hemoglobin concentration, hemato-
crit, mean corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), mean corpuscular hemoglobin con-
centration (MCHC), reticulocyte ratio, platelet count and 
differential leukocyte counts were determined. 
Biochemical analyses
Biochemical examinations were performed using blood 
collected into plain tubes. Blood samples were centrifuged 
at 3 000 rpm for 5 minutes. The serum was collected for 
assays. The following biochemical assays were performed 
using the SELECTRA JUNIOR Version 04 autoanalyzer 
(Vital Scientific, Spankeren, The Netherlands): total 
bilirubin (TBIL), direct bilirubin (DBIL), aspartate amino 
transferase (AST), alanine amino transferase (ALT), total 
protein (TP), albumin (ALB), globulin (GB), alkaline 
phosphatase (ALP), γ-glutamyltranspetidase (γ-GT), urea 
(URE), creatinine (CR). 
Statistical analysis
The statistical analysis of the data was done using SPSS 
(Statistical Package for Social Sciences) version 17.0. All 
data was expressed as Mean ± SD. Statistical difference 
was established using the independent Student’s t-test 
for paired and unpaired data. A probability value of p 
≤ 0.05 was considered statistically significant. For mul-
tiple groups, analysis of variance (ANOVA) was used to 
determine statistical differences. p-values ≤ 0.05 were 
considered significant. Multiple regression analysis was 208
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performed to determine predictive indicators of toxicity 
and their relationship with dependent variables.
Results
Urine analysis for pH, protein, glucose, ketone bodies, 
bilirubin, occult blood and urobilinogen were negative.
Hematological parameters did not show significant 
differences between C and LD groups (Table 1). Slightly 
greater differences were noted for WBC of the C group 
(8.78 × 103/μl) and LD group (6.44  ×  103/μl). Similarly, 
the platelet count was slightly lower for the LD group 
(793.6 × 103/μl) compared to the C group (812.8 × 103/μl). 
These differences, however, were not statistically signifi-
cant. Additionally, at 5 000 mg/kg b.w., slight WBC differ-
ences were observed for the C group (8.78 × 103/μl) and 
HD group (5.94 × 103/μl) that were insignificant (Table 1). 
Table 2 shows renal function determined by urea and 
creatinine levels. Urea values were 7.6  ±  1.1  mmol/l (C 
group), 8.1 ± 2.1 mmol/l (LD group) and 8.7 ± 2.3 mmol/l 
(HD group). The differences between the groups were insig-
nificant. Creatinine was reduced from 67.9 ± 9.7 μmol/l (C) 
to 59.4 ± 17.2 μmol/l (LD) and to 56.5 ± 17.3 μmol/l (HD). 
Creatinine differences were not significant. For the liver 
function test, total protein, albumin and globulin showed 
slight yet insignificant decreases in the LD and HD 
groups. Total bilirubin decreased from 2.1  ±  0.7  μmol/l 
(C group) to 0.5 ± 0.1 μmol/l (LD group). However, there 
was a slight increase to 2.2  ±  1.4  μmol/l when the HD 
extract was administered. Nevertheless, changes were not 
significant. Similarly did the direct and indirect bilirubin 
levels decline non-significantly in the LD group. In the 
HD group, direct and indirect bilirubin levels were virtu-
ally unchanged (Table 2). ALT levels were slightly reduced 
in the LD group. There was a further reduction after 
the HD administration. However, differences were not 
significant. AST declined in the LD group (144 ± 44 U/l) 
compared to the C group (159  ±  42  U/l) but remained 
unchanged in the HD group (159 ± 46 U/l). Changes were 
not significant. Mean ALP level was 444  ±  36  U/l in the 
C group, 388 ± 136 U/l in the LD group and 420 ± 127 U/l 
in the HD group. The differences were insignificant. 
Although γ-GT increased from 1.4 ± 0.68 U/l (C group) to 
1.9 ± 0.71 U/l (LD group), the difference was not signifi-
cant. Contrary to the increase in γ-GT observed after the 
LD administration, γ-GT decreased from 1.4 ± 0.68 U/l (C 
group) to 1.1 ± 0.68 U/l in the HD group. The differences 
were not significant.
Discussion
International opinion and regulations relating to human 
health necessitate that every new pharmaceutical drug 
be tested for its safety before it is administered to human 
volunteers and patients. Toxicity studies in appropriate 
animal models are therefore commonly used to assess 
the potential health risk to humans. Such toxicity stud-
ies assess the hazard, namely the basic toxicity of the 
substance, and the risk is determined by considering the 
probability of exposure to a particular hazard at certain 
levels (Klaassen & Eaton, 1991). This is a key stage in 
Table 1. Table of hematological indices of the Control group, Low 
Dose group (LD = 2 000 mg/kg b.w.) and High Dose group (HD = 
5 000 mg/kg b.w.) on day 15 after the administration of P. niruri aque-
ous leaf extract on Sprague-Dawley rats on day 1. 
Variable Control LD HD p-value
WBC × 103/ml 8.8 ± 2.0 6.4 ± 2.5 5.9 ± 2.6 NS
RBC × 106/ml 6.2 ± 0.4 6.3 ± 1.7 6.1 ± 1.6 NS
HGB g/dl 12.1 ± 0.6 12.2 ± 3.2 11.9 ± 3.2 NS
HCT % 39.4 ± 1.7 39.3 ± 10.6 38.3 ± 10.3 NS
MCV fl 63.3 ± 2.0 62.9 ± 17.0 63.1 ± 16.7 NS
MCH pg 19.4 ± 0.6 19.5 ± 5.3 19.6 ± 5.2 NS
MCHC g/dl 30.7 ± 0.4 31.0 ± 8.5 31.1 ± 8.3 NS
PLT × 103/ml 813 ± 261 794 ± 259 782.8 ± 248.6 NS
LYM% 86.5 ± 3.1 87.3 ± 23.4 87.5 ± 23.1 NS
LYM × 103/ml 7.6 ± 1.7 5.6 ± 2.1 5.2 ± 2.3 NS
RDW-SD fl 31.8 ± 0.6 31.5 ± 8.7 30.9 ± 8.4 NS
RDW-CV % 12.6 ± 0.3 12.3 ± 3.4 12.0 ± 3.3 NS
PDW fl 7.3 ± 0.3 6.9 ± 1.9 7.4 ± 2.0 NS
MPV fl 6.4 ± 0.1 6.1 ± 1.7 6.4 ± 1.7 NS
P-LCR % 4.4 ± 0.6 3.6 ± 1.1 4.9 ± 1.6 NS
NS = Not Significant; WBC = White Blood Cells; RBC = Red Blood Cells; HGB = 
Hemoglobin; HCT = Hematocrit; MCV = Mean Corpuscular Volume; MCH = Mean 
Corpuscular Hemoglobin; MCHC = Mean Corpuscular Hemoglobin Concentra-
tion; PLT = Platelet; LYM % = Lymphocytes Percentage; LYM = Lymphocyte Count; 
RDW-SD = Standard Deviation in Red Cell Distribution Width; RDW-CV = Coeffi-
cient of Variation in Red Cell Distribution Width; PDW= Platelet Distribution Width; 
MPV= Mean Platelet Volume; P-LCR= Platelet Larger Cell Ratio
Table 2. Table of biochemical indices of the Control group, Low 
Dose group (LD = 2 000 mg/kg b.w.) and High Dose group (HD = 
5 000 mg/kg b.w.) on day 15 after administration of P. niruri aqueous 
leaf extract on Sprague-Dawley rats on day 1. 
Variable Control LD HD p-value
URE  mmol/l 7.6 ± 1.1 8.1 ± 2.1 8.7 ± 2.3 NS
CR μmol/l 67.9 ± 9.7 59.4 ± 17.2 56.5 ± 17.3 NS
TP g/l 60.1 ± 5.3 57.4 ± 15.5 55.0 ± 15.6 NS
ALB g/l 36.6 ± 2.8 35.0 ± 9.4 33.8 ± 9.5 NS
GB g/l 23.5 ± 2.6 22.4 ± 6.1 21.2 ± 6.1 NS
DBIL  μmol/l 1.2 ± 0.6 0.7 ± 0.5 1.1 ± 0.6 NS
IBIL μmol/l 0.9 ± 0.4 0.3 ± 0.1 1.1 ± 1.3 NS
TBIL  μmol/l 2.1 ± 0.7 0.5 ± 0.1 2.2 ± 1.4 NS
GGT U/l 1.4 ± 0.7 1.9 ± 0.7 1.1 ± 0.7 NS
ALT U/l 129 ± 20 114 ± 34 107 ± 36 NS
AST U/l 159 ± 42 144 ± 44 159 ± 46 NS
ALP U/l 444 ± 36 388 ± 136 420 ± 127 NS
NS = Not Significant; URE = urea; CR= creatinine; TP = total protein; ALB = albumin; 
GB = globulin; DBIL = direct bilirubin; IBIL = indirect bilirubin; TBIL = total bilirubin; 
GGT = γ-glutamyltranspeptidase; ALT = alanine aminotransferase; AST = aspartate 
aminotransferase; ALP = alkaline phosphatase209
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ensuring the safety of drugs and an acute toxicity study is 
just one of the batteries of toxicity tests that are used for 
such purposes. 
Acute toxicity tests provide preliminary information 
on the toxic nature of a material for which no other toxi-
cological information is available. Such information can 
be used to: (i) deal with cases of accidental ingestion of a 
large amount of the material; (ii) determine possible target 
organs that should be scrutinized and/or special tests that 
should be conducted in repeated-dose toxicity tests; and 
(iii) select doses for short-term and sub-chronic toxicity 
tests when no other toxicology information is available 
(Gad & Chengelis, 1988). Furthermore, the majority 
of pharmaceutical companies use only acute toxicity 
studies to determine the minimum lethal or maximum 
non-lethal dose. In exceptional circumstances, the infor-
mation from acute toxicity studies is used in dose-setting 
for other studies (NC3RS, 2007) and in such cases, the 
pathological examination is usually limited to macro-
scopic observations so that target organs are generally 
identified. Additionally, acute toxicity measurements help 
to determine the therapeutic index, i.e. the ratio between 
the pharmacologically effective dose and the lethal dose 
in the same strain and species, as well as accurately eluci-
date the toxicity of the medicinal plant (Klaassen & Eaton, 
1991). The incorporation of all available information can 
help in reducing the hesitation in deciding to use herbal 
medicinal products (HMP). 
Although HMPs are widely considered to be of lower 
risk compared with synthetic drugs, they are not com-
pletely excluded from the possibility of having toxic or 
other adverse effects (De Smet, 2004). There are, however, 
challenges unique to HMPs. Often, deficiencies such as 
under-reporting of adverse reactions, general lack of 
toxicological information on herbs, and the quality of the 
reported information present challenges when signals of 
safety concern arise.
The lack of adequate scientific evidence on the safety 
of P. niruri is often a major issue to the acceptance and 
use of this medicinal plant. In this study, the plant was 
successfully identified as P. niruri and therefore the 
results are not extrapolated beyond this species. The 
absence of toxidromes was evident at the time of extract 
administration and thereafter. The biochemical data, 
mainly the hepatobiliary and renal systems, did not sug-
gest any toxicity. Furthermore, there were no statistical 
differences between the low dose (2 000 mg/kg b.wt.) and 
the high dose (5  000  mg/kg b.wt.) extract administra-
tion. Hematologically, the present data did not show any 
adverse effect either at the low or the high dose. Thus the 
aqueous leaf extract of P. niruri can be considered non-
toxic at the acute level and consequently, the LD50 of P. 
niruri aqueous leaf extract is more than 5 000 mg/kg b. wt. 
Because the existing literature on the toxicity of 
Phyllanthus niruri is limited, coupled with environmental 
factors including climate, soil and water changes that may 
have modified the chemical composition of the plant, 
retesting after long periods is imperative to validate any 
existing data in the light of newer analytical tools available. 
With single-ingredient products, it is important that the 
plant part used be identified. Knowledge of the specific 
plant part, associated with suspected adverse reactions 
or toxicity, improves assessment of previously reported 
adverse effects. Additionally, it must be recognized that 
various extraction procedures of the same herb, or plant 
part, produce finished products of varying chemical 
composition (Williamson et al., 1996) and therefore data 
interpretation must be judiciously assessed. From this 
study it is concluded that the aqueous leaf extract of P. 
niruri has an LD50 greater than 5000 mg/kg b.w. with no 
adverse effect of this dose after a single administration.
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